Display again
SNCTP000001327 | NCT02451111

SAKK 35/14 Rituximab in Kombination mit Ibrutinib oder Placebo in nicht vorbehandelten Patienten mit einem fortgeschrittenen follikulären Lymphom mit Therapiebedarf. Eine randomisierte, doppelblindePhaseIIStudie

Data source: BASEC (Imported from 30.11.2021), WHO (Imported from 18.04.2021)
Changed: 21.02.2021
Disease category: Non-Hodgkin Lymphoma

Brief description of trial (Data source: BASEC)

Mit der Studie SAKK 35/14 will man nun herausfinden, ob die Kombination der Wirkstoffe Rituximab und Ibrutinib für die Patienten noch mehr Vorteile hat. Diese Kombination hat sich in anderen Studien bereits als gut verträglich und wirksam erwiesen. In der Studie SAKK 35/14 erhalten Patienten mit follikulärem Lymphom, die erstmals eine Behandlung mit Medikamenten benötigen, während zwei Jahren entweder Rituximab und placebo oder eine Kombinationsbehandlung aus Rituximab und Ibrutinib. Während der Therapie und auch danach werden die Patienten regelmässig vom Arzt kontrolliert, um die Verträglichkeit und Wirksamkeit der Behandlung zu überwachen . Es handelt sich um eine doppel blinde Studie (dh. weder der Patient noch der Arzt wissen, ob sie Ibrutinib oder Placebo erhalten).

Health conditions investigated (Data source: BASEC)

Fortgeschrittenen follikulären Lymphom

Health conditions (Data source: WHO)

Follicular Lymphoma

Rare disease (Data source: BASEC)


Intervention investigated (e.g. drug, therapy or campaign) (Data source: BASEC)

Rituximab in Kombination mit Ibrutinib oder Placebo während 24 Monaten

Interventions (Data source: WHO)

Drug: Ibrutinib;Drug: Rituximab

Criteria for participation in trial (Data source: BASEC)

Histologisch bestätigtes fortgeschrittenen follikulären (FL) Lymphom mit Therapiebedarf; mind. eine messbare Läsion ≥ 15 mm; ausreichende Blut, Leber, NIerenwerte

Exclusion criteria (Data source: BASEC)

Vorherige Therapie gegen das FL; Behandlung mit CYP3A-Inhibitoren und Antikoagulantien

Inclusion/Exclusion Criteria (Data source: WHO)

Inclusion Criteria:

- Written informed consent according to ICH/GCP guidelines

- Histologically confirmed FL CD20+; grade 1, 2, 3a; stage III+IV; stage II not suitable
for radiotherapy; all FLIPI

- Tumor specimens (slides or block) available for pathological review

- In need of systemic therapy (at least one of the following indications must be

- Symptomatic disease

- Bulky disease (= 6 cm)

- Steady, clinically significant progression over at least 3 months of any tumor

- B-symptoms (weight loss > 10% in 6 months, drenching night sweats, fever > 38°C
not due to infection)

- Anemia (hemoglobin < 100 g/L) or thrombocytopenia (platelets 50-100 x 109/L) due
to lymphoma

- At least one two-dimensionally measurable lesion with a longest diameter (LDi) = 15 mm
in contrast-enhanced 18F-FDG PET/CT* scan

- FDG-avid tumor lesion in contrast-enhanced 18F-FDG PET/CT* scan

- Age 18-85 years

- WHO performance status 0-2

- Adequate bone marrow function:

- Absolute neutrophil count (ANC) > 1.0 x 109/L independent of growth factor

- Platelets = 100 x 109/L or = 50 x 109/L if bone marrow involvement independent of
transfusion support in either situation

- Adequate hepatic function:

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x upper
limit of normal (ULN)

- Total bilirubin = 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or
of non-hepatic origin

- Adequate renal function:

• Serum creatinine = 2 x ULN and corrected calculated creatinine clearance = 40

- Women of childbearing potential have a negative serum (beta-human chorionic
gonadotropin) or urine pregnancy test at Screening.

- Patient compliance and geographic proximity allow proper staging and follow-up.

Exclusion Criteria:

- Tumor bulk requiring fast response

- Known central nervous system lymphoma

- Previous systemic FL therapies

- Major surgery 4 weeks prior to randomization

- Previous or concomitant malignancy diagnosed within 3 years with the exception of
adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer

- History of stroke or intracranial hemorrhage within 6 months prior to randomization

- Clinically significant cardiovascular diseases such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
the New York Heart Association Functional Classification

- Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or
active Hepatitis B Virus infection or any uncontrolled active systemic infection
requiring intravenous (i.v.) antibiotics

- Concomitant diseases that require anticoagulation with warfarin or equivalent vitamin
K antagonists (eg. phenprocoumon), factor Xa inhibitors (e.g. rivaroxaban, apixaban),
direct thrombin inhibitors (e.g. dabigatran) or platelet inhibitors/antiplatelet
agents. Aspirin is allowed (up to 300 mg/d).

- Concomitant diseases that require treatment with strong or moderate CYP3A inhibitors
(see http://medicine.iupui.edu/clinpharm/ddis/clinical-table/)

- Any concomitant drugs contraindicated for use with the trial drugs according to the
approved product information or known hypersensitivity to trial drugs

- Concurrent treatment with other experimental drugs or other anticancer therapy,
treatment in a clinical trial within 30 days prior to trial entry

- Vaccinated with live, attenuated vaccines 4 weeks prior to randomization

- Any life-threatening illness, medical condition, or organ system dysfunction which, in
the Investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of Ibrutinib capsules, or put the study outcomes at undue

- Psychiatric disorder precluding understanding information of trial related topics,
giving informed consent or interfering with compliance for oral drug intake

- Women who are pregnant or breastfeeding

- Patients regularly taking corticosteroids during the last 4 weeks, unless administered
at a dose equivalent to Prednisone = 15 mg/day for indications other than lymphoma or
lymphoma-related symptoms

Further information on the trial in WHO primary registry


Further information on the trial from WHO database (ICTRP)


Further information on trial

Date trial registered


Incorporation of the first participant


Recruitment status

Active, not recruiting

Academic title (Data source: WHO)

Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.

Type of trial (Data source: WHO)


Design of the trial (Data source: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Phase (Data source: WHO)

Phase 2

Primary end point (Data source: WHO)

CR at 24 months determined by PET/CT scan by the IRR panel

Secundary end point (Data source: WHO)

CR at 30 months determined by PET/CT scan by the IRR panel;MRD evaluation;Overall response (OR);Duration of complete response (DUR);Progression-free survival (PFS) (PFS);Adverse Events (AEs);Time to next anti-lymphoma therapy (TTNT);Event-free survival (EFS)

Contact information (Data source: WHO)

Please refer to primary and secondary sponsors

Trial results (Data source: WHO)

Results summary

no information available yet

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data

no information available yet

Trial sites

Trial sites in Switzerland (Data source: BASEC)

Aarau, Baden, Basel, Bellinzona, Bern, Brig, Bruderholz, Chur, Geneva, Liestal, Luzern, Olten, Sion, St. Gallen, Thun, Winterthur, Zurich

Countries (Data source: WHO)

Austria, Denmark, Finland, Norway, Sweden, Switzerland

Contact for further information on the trial

Details of contact in Switzerland (Data source: BASEC)

Secondini Chiara
+41 31 389 91 91

Contact for general information (Data source: WHO)

Emanuele Zucca, Prof;Bjørn Østenstad, MD;Björn Wahlin, MD
Oncology Institute of Southern Switzerland IOSI, Bellinzona;Oslo University Hospital;Karolinska University Hospital, Stockholm

Contact for scientific information (Data source: WHO)

Emanuele Zucca, Prof;Bjørn Østenstad, MD;Björn Wahlin, MD
Oncology Institute of Southern Switzerland IOSI, Bellinzona;Oslo University Hospital;Karolinska University Hospital, Stockholm

Principal Sponsor/Investigator

Principal sponsor (Data source: WHO)

Swiss Group for Clinical Cancer Research

Additional sponsors (Data source: WHO)

Nordic Lymphoma Group

Authorisation by the ethics committee (Data source: BASEC)

Name of the authorising ethics committee (for multicentre studies only the lead committee)

Comitato etico cantonale Ticino

Further trial identification numbers

Secondary ID (Data source: WHO)

SAKK 35/14